Vivos Therapeutics, Inc. (VVOS) stock
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.10+0.00 (+2.40%)
Close on Nov 13, 2026Market cap $1.97MP/E –Yield –
Vivos Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Vivos Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -121.8%. For fiscal 2025 it was -121.4%, against -74.1% the year before. The highest annual figure on record is -74.1% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -121.4% | −47.3 |
| FY2024 | Dec 31, 2024 | -74.1% | +24.3 |
| FY2023 | Dec 31, 2023 | -98.4% | +50.4 |
| FY2022 | Dec 31, 2022 | -148.8% | −28.7 |
| FY2021 | Dec 31, 2021 | -120.2% | −27.9 |
| FY2020 | Dec 31, 2020 | -92.3% | +2.1 |
| FY2019 | Dec 31, 2019 | -94.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -106.4% | +24.9 |
| Q1 FY2026 | Mar 31, 2026 | -149.4% | −21.3 |
| Q4 FY2025 | Dec 31, 2025 | -180.3% | −103.8 |
| Q3 FY2025 | Sep 30, 2025 | -79.6% | −11.8 |
| Q2 FY2025 | Jun 30, 2025 | -131.2% | −83.6 |
| Q1 FY2025 | Mar 31, 2025 | -128.1% | −18.1 |
| Q4 FY2024 | Dec 31, 2024 | -76.4% | +54.7 |
| Q3 FY2024 | Sep 30, 2024 | -67.8% | −4.4 |
| Q2 FY2024 | Jun 30, 2024 | -47.6% | +115.2 |
| Q1 FY2024 | Mar 31, 2024 | -110.1% | −65.9 |
| Q4 FY2023 | Dec 31, 2023 | -131.1% | +23.0 |
| Q3 FY2023 | Sep 30, 2023 | -63.4% | +64.6 |
| Q2 FY2023 | Jun 30, 2023 | -162.8% | +4.3 |
| Q1 FY2023 | Mar 31, 2023 | -44.2% | +102.1 |
| Q4 FY2022 | Dec 31, 2022 | -154.2% | +14.1 |
| Q3 FY2022 | Sep 30, 2022 | -128.0% | −8.0 |
| Q2 FY2022 | Jun 30, 2022 | -167.1% | −77.2 |
| Q1 FY2022 | Mar 31, 2022 | -146.3% | −47.7 |
| Q4 FY2021 | Dec 31, 2021 | -168.3% | +20.7 |
| Q3 FY2021 | Sep 30, 2021 | -120.0% | −64.9 |
| Q2 FY2021 | Jun 30, 2021 | -89.9% | −46.7 |
| Q1 FY2021 | Mar 31, 2021 | -98.6% | −17.8 |
| Q4 FY2020 | Dec 31, 2020 | -189.0% | – |
| Q3 FY2020 | Sep 30, 2020 | -55.1% | – |
| Q2 FY2020 | Jun 30, 2020 | -43.2% | – |
| Q1 FY2020 | Mar 31, 2020 | -80.7% | – |
See a number that looks wrong?